Today's lineup spans engineering, ad tech and three healthcare names — most with fresh earnings already on the tape, and two still waiting on readouts that matter.
Fluor designs and builds the heavy stuff — plants, mines, power projects — and electricity-hungry data centers are pushing new project awards sharply higher. Watch the backlog: turning it into profit is the whole story now.
View Chart →Roivant runs a family of small drug subsidiaries, each chasing one idea, and its immune-disease programs are the ones carrying the story. The next read is the FDA's call on its lead inflammation drug.
View Chart →Guardian fills the daily prescriptions for assisted-living and long-term care communities, and it keeps buying up local pharmacies to widen that map. Watch whether new residents outrun federal drug-price cuts.
View Chart →Viant sells software that lets brands buy streaming-TV ads automatically, and its new tool that runs whole campaigns on its own is what's pulling budgets in. Monday's report is the first real read on adoption.
View Chart →AbCellera runs a discovery engine that hunts down antibody drugs, and big pharma keeps paying up front for access to it. But the whole story now is its own hot-flash treatment, with mid-stage data due any day.
View Chart →This newsletter is for informational purposes only and does not constitute financial advice. TradersPro and its contributors are not registered investment advisors. Always conduct your own due diligence before making investment decisions. Past performance is not indicative of future results.
